Basic Psychedelic Neuroscience

Evidence reviewed: September 27, 2026.

The brain image above is illustrative. It is not a before-and-after comparison or evidence of a treatment effect.

The short explanation

Classic psychedelics temporarily alter the organization of brain activity. Some usual network boundaries become less distinct, and perception, emotion and the sense of self can change profoundly. One leading interpretation is that familiar predictions become less dominant, creating room to examine old patterns. That interpretation is useful, but not settled. Greater flexibility does not guarantee a helpful outcome. Network mega-analysis (2026); Carhart-Harris & Friston (2019).

The person, substance, setting and what happens afterward all matter. Read What Are Psychedelics Doing in the Brain? for the full explanation.

A little deeper

Receptors: the starting point

Neurons send electrical and chemical signals. Receptors respond to chemical messengers and influence cell activity. The key-and-lock metaphor is a useful introduction, but receptors interact with complex cellular systems. They do not hold particular thoughts or feelings.

Psilocin, LSD and DMT activate serotonin 5-HT2A receptors. Human studies that block these receptors or measure how much of the drug binds to them support their role during the experience. Other receptors contribute; serotonin does more than regulate happiness. MDMA primarily increases the release of chemical messengers, including serotonin, through proteins called transporters, while ketamine has a different starting mechanism, involving NMDA receptors. Preller et al. (2018); Madsen et al. (2019); MDMA pharmacology review (2025); Neural mechanisms review (2022).

Networks and the default mode network

“Functional connectivity” describes how activity in different brain regions varies together. It does not mean new wiring has grown. Across classic psychedelics, more closely related activity between systems that interpret information and systems that process the senses is a more consistent finding than a uniform loss of connectivity within every network. The DMN participates in self-related thought and memory, among other functions. It remains active; it is not an ego switch. Network mega-analysis (2026); Doss et al. (2022).

fMRI measures blood-oxygen signals, not thoughts or neuronal firing directly. Drug-related vascular changes are one limitation. EEG and MEG offer other perspectives. Findings are more convincing when different methods point to the same explanation. Neurovascular study (2025).

Predictive processing and REBUS

Brains interpret information in light of expectations. REBUS proposes reduced confidence in high-level predictions, allowing sensations, emotions and other information greater influence. DMT imaging shows changes in cortical hierarchy compatible with this broad idea, but does not directly measure the weight of a personal belief. Carhart-Harris & Friston (2019); Timmermann et al. (2023).

Some accounts instead emphasize stronger expectations at particular levels of perception. Other theories focus on the thalamus, which helps relay information, or the claustrum, a thin structure thought to help coordinate brain activity. They offer competing or complementary explanations; no single model has won. Neural mechanisms review (2022); Doss et al. (2022); Preller et al. (2019).

Entropy, complexity and criticality

Several studies using EEG and MEG, which record electrical and magnetic activity, have found more varied signals during the experience. The entropic brain hypothesis relates this diversity to the breadth of experience. Criticality describes a proposed transition between stable and disorderly dynamics. These concepts help organize research; they do not measure wisdom or prove that greater complexity is healthier. Schartner et al. (2017); Carhart-Harris (2026).

Recent research using more than one brain-measurement method also finds context-specific organization under psilocybin. Increased diversity can coexist with structured responses to the surroundings. Its proposed “embeddedness” account is a developing interpretation, not a proven explanation of recovery. Stoliker et al. (2026).

Emotion, memory and flexibility

Emotions and memories can feel different, but there is no simple fear centre that switches off. Feeling certain about an insight does not verify it. A vivid recollection is not an accurate recording by default. Studies of memory and emotional processing need to be read by substance and task. Doss et al. (2023); MDMA emotion meta-analysis (2025).

Variation in brain activity, performance on a thinking task and the ability to respond differently in daily life are different measurements. A change in one cannot stand in for the others or for clinical improvement. Doss et al. (2021).

Plasticity and the proposed window

Animal and cell studies support changes in synapses and learning under specific conditions. Human evidence remains more indirect. A recent diffusion-MRI finding is exploratory; a small human PET study found no significant overall rise in a synaptic marker. We should not promise new human brain connections or a fixed window for change. Lima da Cruz et al. (2024); Lyons et al. (2026); Johansen et al. (2026).

Entheo’s fresh-snow metaphor can still help: familiar ski tracks may feel less compulsory. It does not mean memories disappear or new routes will be better. Reflection, relationships and daily actions may shape what follows; the best timing and form of integration are not established by neuroscience. Carhart-Harris et al. (2018).

Mechanism is not the same as benefit

Persistent network changes and symptom improvements sometimes correlate. Such associations cannot establish which change caused which. Expectations, support and the drug can all contribute, and distinguishing them is difficult. A more intense experience does not necessarily mean a better outcome. Daws et al. (2022); BMJ evidence review (2026).

Continue with the Preparation Guidebook, medication considerations and integration resources.

Sources and further reading

Primary human studies, preclinical studies and explanatory models answer different questions. The labels below make those differences visible.

1. Madsen et al. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
   Human PET; receptor occupancy correlates with intensity, not proof of clinical benefit.
2. Preller et al. (2018). Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor
   Human randomized pharmacological blockade; supports receptor contribution to acute effects.
3. Carhart-Harris & Friston (2019). REBUS and the Anarchic Brain
   Theoretical synthesis; relaxed precision of high-level priors is a model, not a universal measured effect.
4. Carhart-Harris et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
   Foundational hypothesis; consciousness interpretation exceeds measurement of signal variability alone.
5. Carhart-Harris (2026). The entropic brain today
   Updated review by model proponent; entropy findings stronger than general claims about consciousness or therapeutic causality.
6. Schartner et al. (2017). Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
   Human MEG reanalysis; increased diversity is not evidence of increased wisdom or guaranteed benefit.
7. An international mega-analysis of psychedelic drug effects on brain circuit function (2026)
   11 datasets, 267 participants; strongest shared finding is increased association–sensory coupling. Within-network decreases selective; methods and drugs heterogeneous.
8. Timmermann et al. (2023). Human brain effects of DMT assessed via EEG-fMRI
   Small controlled human study: increased connectivity, reduced segregation and compressed cortical hierarchy; not direct measurement of personal beliefs.
9. Preller et al. (2019). Effective connectivity changes in LSD-induced altered states of consciousness in humans
   Human pharmacological fMRI with model-based directionality; specific thalamocortical changes, not proof that a filter opens globally.
10. Doss et al. (2022). Models of psychedelic drug action: modulation of cortical-subcortical circuits
    Review compares CSTC, REBUS and claustrum-centered models; anatomical alternatives remain under investigation.
11. The neural basis of psychedelic action (2022)
    Review separates receptors, cells and circuits; discusses REBUS, strong-prior, CSTC and CCC models.
12. Stoliker et al. (2026). Psychedelics align brain activity with context
    62 participants, fMRI/EEG and multiple contexts; open-label baseline-to-drug design, no placebo comparison. Neural patterns and next-day mindset associations are not proven clinical mediation.
13. Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function (2025)
    Mouse neuronal/hemodynamic experiments plus human imaging analyses; vascular contribution complicates BOLD interpretation, does not invalidate all fMRI.
14. Siegel et al. (2024). Psilocybin desynchronizes the human brain
    Seven intensively scanned healthy adults; acute widespread changes and more selective persistent hippocampal–DMN change. Small sample, not whole-brain reset.
15. Daws et al. (2022). Increased global integration in the brain after psilocybin therapy for depression
    Imaging in two depression trials; network changes correlated with symptom improvement. Correlation does not establish mediation or necessity.
16. Doss et al. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
    24-patient open-label treatment study; set-shifting improved, but cognitive and depression improvements did not correlate. Neural flexibility is not psychological flexibility.
17. Lyons et al. (2026). Human brain changes after first psilocybin use
    28 healthy participants, fixed-order low-dose then active comparison, exploratory non-preregistered hypotheses. Diffusion MRI is an indirect, nonspecific structural measure; no general lasting functional change.
18. Nardou et al. (2023). Psychedelics reopen the social reward learning critical period
    Mouse social reward assay; durations and results cannot prescribe a human integration window.
19. Vargas et al. (2023). Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
    Cell/animal evidence for intracellular receptor mechanism; not direct clinical mechanism proof.
20. Moliner et al. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
    Preclinical alternative molecular account; relevance and receptor requirements for human benefit unresolved.
21. Johansen et al. (2026). Psilocybin’s effect on human brain synaptic plasticity
    15 healthy people, SV2A PET at one week: no significant overall increase. Setting comparisons exploratory; no proof of environment causing synaptic growth.
22. Lima da Cruz et al. (2024). Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
    Mixed substances/species/endpoints; systematic search January 2023, so cannot substitute for newer primary evidence.
23. On the meaning of ‘plasticity’ in neuroscience and mental health research and its relation to the action of psychedelic therapy (2026)
    Conceptual review; structural change, capacity for learning and dynamical flexibility are related but distinct constructs.
24. Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug (2025)
    Pharmacology review: transporter-mediated monoamine release; cardiovascular and temperature risks. Not a classic psychedelic mechanism.
25. A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans (2025)
    Controlled acute social/emotion tasks; emotional empathy and emotion recognition differ, not proof of PTSD memory repair.
26. Doss et al. (2018). MDMA impairs both the encoding and retrieval of emotional recollections
    Human laboratory memory; cannot equate vivid recollection with accuracy or transfer precise effects to every psychedelic.
27. Doss et al. (2023). The acute effects of psychoactive drugs on emotional episodic memory encoding, consolidation, and retrieval: A comprehensive review
    Human laboratory evidence varies by drug and memory process; autobiographical recall and certainty do not verify an event.
28. Carhart-Harris et al. (2018). Psychedelics and the essential importance of context
    Theory and observational evidence; support/context matter, but optimal integration method and causal contribution not established.
29. Psychedelic medicine: mechanisms, evidence, and translation to practice (2026)
    State-of-the-art clinical review; masking/expectancy and bundled psychological support limit mechanism-to-outcome inference.
30. The science of psychedelic medicine (2026)
    Major integrative review proposes acute desynchronization and later plasticity; explanatory synthesis, not proof of a universal therapeutic sequence.
31. Shao et al. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
    Direct mouse spine imaging; not demonstration of new connections in living human brains.
32. Doss et al. (2024). Psilocybin and 2C-B at Encoding Distort Episodic Familiarity
    Controlled 20-person laboratory study; encoding and familiarity effects, not a test of the truth of autobiographical memories.